member mufg global financi group
report better expect result morn
adjust ebitda adjust ep exceed estim
consensu either near top-end manag
guidanc rang industri fundament remain strong
continu gener sale momentum highlight qoq
growth book qoq growth backlog constant fx
revenu growth deceler quarter vs
impli guidanc assum deceler
rang despit near-term top-lin growth pressur believ
well-posit re-acceler growth medium-term
maintain neutral rate believ current valuat fairli
reflect compani growth outlook
result report adjust ep yoy
high-end manag guidanc rang
our/consensu estim versu model
out-performance larg driven oper result
lower net interest expens partial off-set
modestli higher tax rate adjust vs estim
revenu total revenu yoy fx adjust
near top-end guidanc
exceed our/consensu estim
revenu growth fx adjust
fx adjust result
fx adjust better
backlog book end backlog includ pass-through
revenu total repres qoq growth
expect convert revenu next twelv
month consist prior quarter ttm net new busi
award book total increas qoq
yoy ttm net book-to-bil increas
ttm backlog coverag increas
book-to-bil
ebitda adjust ebitda yoy fx adjust
exceed high-end guidanc
our/consensu estim out-performance
share
import disclosur analyst certif begin page
attribut oper execut synergi realiz
cost contain initi adjust ebitda margin
increas yoy qoq
debt capit deploy ocf total
yoy higher qoq net debt adjust
ebitda qoq repurchas stock
quarter brine ytd total remain share
buy-back author
recent win call manag highlight
competit oce market sinc roll new solut
decemb recent win includ previously-announc roch
saa technolog suit agreement roll user
across market real-world side sign collabor
genom england launch first real-world research platform
integr clinic genom data
guidanc revenu guidanc adjust rang
reflect increas low-end commensur
decreas high-end adjust ebitda rang increas
midpoint adjust ep rang
increas midpoint prior
impli guidanc revenu yoy growth
adjust ebitda yoy growth reflect
margin adjust ep yoy
estim adjust model reflect out-performance
updat guidanc new adjust ep estim
yoy adjust ep estim remain
unchang yoy adjust ep estim
increas yoy
valuat current trade premium peer group
price-to-earnings basi current valuat fairli reflect iqv
medium-term growth outlook view new per share target
base multipl
dollar share million except ep
compani report research estim bloomberg
oper resultsactualmufgcon guidancemufgcon total revenu bpssg total bpsadjust adjust ebitda expens pre-tax adjust tax bpsless nci ni weight average new biz award ttm backlog book bill backlog vs estimate svarianceestim
dollar million except ep compani report musa
incom yoy yoy growth constant ebitda yoy integr revenu purchas acct adj ebitda yoy adj ebitda margin constant oper oper debt incom unconsolid attribut pre-tax adjust tax adjust tax incom minor interest effect ni yoy average share yoy us equiti research
believ iqvia benefit industri tailwind around bio-
pharmaceut spend clinic trial outsourc compani
invest real-world insight next-gen cro offer
may translat competit advantag contribut acceler
top-lin growth opportun howev may take time servic
offer evolv contribut revenu earn growth
current trade premium peer group
price-to-earnings basi current valuat fairli reflect iqv medium
term growth outlook view per share target base
multipl adjust ep estim
risk recommend downsid upsid includ
acceler slowdown bio-pharmaceut research
develop gain loss contract chang healthcar
regulatori environ chang reimburs level chang
competit landscap
iqvia world largest clinic research organ cro
provid biopharmaceut client outsourc research
develop product commerci form
merger quintil im health octob iqvia one
largest comprehens collect world-wide healthcar
inform compani expect gener revenu
carri contract backlog excess
